Although the combination of Fgf15 overexpression and PPARα activation had an excellent effect on promoting weight loss and reducing hepatic steatosis, the dual treatments led to increased liver injury and expression of genes in inflammation, fibrosis, and antioxidation. This evidence concerns the gene PPARA and fatty liver disease.